{"id":658619,"date":"2023-07-07T03:28:01","date_gmt":"2023-07-07T03:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=658619"},"modified":"2023-07-07T03:28:01","modified_gmt":"2023-07-07T03:28:01","slug":"gastric-ulcer-pipeline-and-clinical-trials-pipeline-analysis-2023-updated-5-companies-are-working-to-improve-the-treatment-of-space-raqualia-pharma-kindredbio-daewoong-pharmaceutical-co","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastric-ulcer-pipeline-and-clinical-trials-pipeline-analysis-2023-updated-5-companies-are-working-to-improve-the-treatment-of-space-raqualia-pharma-kindredbio-daewoong-pharmaceutical-co_658619.html","title":{"rendered":"Gastric Ulcer Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 5+ Companies are working to improve the Treatment of Space | RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1688626589.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastric Ulcer Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 5+ Companies are working to improve the Treatment of Space | RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co\" src=\"https:\/\/www.abnewswire.com\/uploads\/1688626589.png\" alt=\"Gastric Ulcer Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 5+ Companies are working to improve the Treatment of Space | RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the Gastric Ulcer pipeline constitutes 5+ key companies continuously working towards developing 5+ Gastric Ulcer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the Gastric Ulcer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Gastric Ulcer clinical trials studies, Gastric Ulcer NDA approvals (if any), and product development activities comprising the technology, Gastric Ulcer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the Gastric Ulcer Pipeline treatment landscape of the report, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Ulcer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Gastric Ulcer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Gastric Ulcer Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.<\/li>\n<li>The leading Gastric Ulcer Companies working in the market include RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co, Pharmaking Ltd., Sam-A Pharm Co. Ltd., Xuanzhu Pharma Co, and others<\/li>\n<li>Promising Gastric Ulcer Pipeline Therapies in the various stages of development include Rebamipide, Omeprazole, PA32540, EC-Aspirin 325 mg, Esomeprazole, Ranitidine, CJ-12420 50 mg QD, Lansoprazole 30 mg QD, TAK-438, PN400 (VIMOVO), Naproxen, and others<\/li>\n<li>Tegoprazan is a gastric acid secretion inhibitor with a new mechanism called potassium-competitive acid blocker (P-CAB) that was created by RaQualia Pharma. P-CAB has a different mechanism from proton pump inhibitors (PPI), which are the first drug of choice for the treatment of gastroesophageal reflux disease (GERD).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Ulcer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Gastric ulcers are a break in the mucosa of the stomach lining that penetrates through the muscularis mucosa and extends more than 5 mm in diameter. When alterations occur to the defense mechanisms of the stomach, it can cause changes in the gastric mucosa which will eventually result in erosion and then ulceration. This activity reviews the evaluation and management of gastric ulcers and explains the role of the inter-professional team in improving care for patients with this condition.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the Gastric Ulcer Pipeline treatment landscape of the report, click here @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Ulcer Emerging Drug Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tegoprazan: RaQualia Pharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Ulcer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 5+ Gastric Ulcer companies which are developing the therapies Gastric Ulcers. The Gastric Ulcer companies which have their Gastric Ulcers drug candidates in the most advanced stage, i.e Phase III include, RaQualia Pharma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Gastric Ulcer Ongoing Clinical Trial Analysis and Medications, click here @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Ulcer Drugs and Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rebamipide: Zhejiang Otsuka Pharmaceutical Co., Ltd\/ Korea Otsuka Pharmaceutical Co., Ltd.<\/li>\n<li>PA32540: POZEN<\/li>\n<li>Esomeprazole: AstraZeneca<\/li>\n<li>CJ-12420 50 mg QD: HK inno.N Corporation<\/li>\n<li>TAK-438: Takeda<\/li>\n<li>Rebamipide and Omeprazole: Otsuka Pakistan Limited<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Ulcer Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Companies in the Gastric Ulcer Therapeutics Market include-<\/strong><\/p>\n<p style=\"text-align: justify;\">RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co, Pharmaking Ltd., Sam-A Pharm Co. Ltd., Xuanzhu Pharma Co, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for Gastric Ulcer Pipeline, click here for Gastric Ulcer Unmet Needs and Analyst Views @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Gastric Ulcer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Gastric Ulcer Companies- RaQualia Pharma, KindredBio, Daewoong Pharmaceutical Co, Pharmaking Ltd., Sam-A Pharm Co. Ltd., Xuanzhu Pharma Co, and others.<\/li>\n<li>Gastric Ulcer Pipeline Therapies- Rebamipide, Omeprazole, PA32540, EC-Aspirin 325 mg, Esomeprazole, Ranitidine, CJ-12420 50 mg QD, Lansoprazole 30 mg QD, TAK-438, PN400 (VIMOVO), Naproxen, and others.<\/li>\n<li>Gastric Ulcer Segmentation: Product Type, Molecule Type, Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on Gastric Ulcer Merger and acquisitions, Licensing Activities @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastric-ulcers-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Gastric Ulcers: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Gastric Ulcers&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Tegoprazan: RaQualia Pharma<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>PMK S005: PharmaKing<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Gastric Ulcers Key Companies<\/li>\n<li>Gastric Ulcers Key Products<\/li>\n<li>Gastric Ulcers- Unmet Needs<\/li>\n<li>Gastric Ulcers- Market Drivers and Barriers<\/li>\n<li>Gastric Ulcers- Future Perspectives and Conclusion<\/li>\n<li>Gastric Ulcers Analyst Views<\/li>\n<li>Gastric Ulcers Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastric-ulcer-pipeline-and-clinical-trials-pipeline-analysis-2023-updated-5-companies-are-working-to-improve-the-treatment-of-space-raqualia-pharma-kindredbio-daewoong-pharmaceutical-co\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastric-ulcer-pipeline-and-clinical-trials-pipeline-analysis-2023-updated-5-companies-are-working-to-improve-the-treatment-of-space-raqualia-pharma-kindredbio-daewoong-pharmaceutical-co\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the Gastric Ulcer pipeline constitutes 5+ key companies continuously working towards developing 5+ Gastric Ulcer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastric-ulcer-pipeline-and-clinical-trials-pipeline-analysis-2023-updated-5-companies-are-working-to-improve-the-treatment-of-space-raqualia-pharma-kindredbio-daewoong-pharmaceutical-co_658619.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-658619","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=658619"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=658619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=658619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=658619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}